News

CAMBRIDGE, Mass. – October 7, 2022 – Caraway Therapeutics today announced that the Company will be participating in two upcoming investor conferences. Caraway’s Chief Executive Officer, Martin D. Williams, will present recent advances in the Company’s TRPML1 program at the Fall Life Sciences Private Company Showcase, co-hosted by BMO Capital Markets, Solebury Strategic Communications and Goodwin in […] » Full Story

CAMBRIDGE, Mass. – October 6, 2022 – Caraway Therapeutics today announced that the Company will be presenting new data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference, taking place October 13, 2022, in New York, New York. Magdalene Moran, Ph.D., President & Chief Scientific Officer of Caraway and Donato del Camino, Ph. D., Vice President […] » Full Story

CAMBRIDGE, Mass. — July 06, 2022 — Caraway Therapeutics today announced that the Company will be participating in the William Blair Biotech Focus Conference, taking place July 13, 2022, in New York City. Caraway’s Chief Executive Officer, Martin D. Williams, will participate in a fireside chat with Myles Minter, PhD, Biotech Equity Research Analyst at William […] » Full Story

CAMBRIDGE, Mass. — March 22, 2022 — Caraway Therapeutics today announced that the Company will be presenting at the Stifel CNS Days event on Tuesday, March 29, 2022, at 3:00pm Eastern Time. Caraway’s Chief Executive Officer, Martin D. Williams, will highlight recent advances in the company’s lead program targeting the lysosomal cation channel, TRPML1, for the […] » Full Story

CAMBRIDGE, Mass. – March 8, 2022 – Caraway Therapeutics today announced that the Company will be presenting at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 9:20am Eastern Time. Caraway’s Chief Executive Officer, Martin D. Williams, will highlight recent advances in the company’s lead program targeting the lysosomal cation channel, TRPML1, for the […] » Full Story

– Esteemed Harvard Medical School Professor Emeritus and HHMI Investigator, Dr. David Clapham, brings world class expertise on ciliary ion channel biology – CAMBRIDGE, MA – March 2, 2022 –  Caraway Therapeutics today announced the appointment of David Clapham, MD, PhD, to the company’s Scientific Advisory Board (SAB). Dr. Clapham is one of the world’s foremost […] » Full Story

CAMBRIDGE, MA – January 26, 2022 – Caraway Therapeutics today announced that the Company has been awarded a third research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This latest grant enables Caraway to further explore the role of TRPML1 activation in alpha-synuclein processing and clearance. It also supports efforts to identify […] » Full Story

CAMBRIDGE, Mass. – November 10, 2021 – Caraway Therapeutics today announced that the Company is scheduled to participate at two upcoming investor conferences. Caraway’s Chief Executive Officer, Martin D. Williams, will provide a company overview at the Jefferies 12th Annual London Healthcare Conference on November 17, 2021, at 5:00 – 5:35 PM GMT (12:00 – 12:35 PM […] » Full Story

CAMBRIDGE, Mass. – September 16, 2021 – Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Thursday, September 23, 2021 at 2:55pm Eastern Time. The presentation will cover recent progress from Caraway’s lead program targeting modulation of the lysosomal cation […] » Full Story

CAMBRIDGE, MA – June 9, 2021 – Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to develop and commercialize Caraway’s small molecule therapeutics targeting TMEM175, a potassium ion channel critical to lysosomal function implicated in both Parkinson’s disease (PD) and other neurodegenerative disorders. TMEM175 is a compelling target with strong […] » Full Story

CAMBRIDGE, MA –March 25, 2021 – Caraway Therapeutics today announced that the Company is scheduled to participate at two upcoming virtual investor events in April 2021. Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel CNS Day on April 1, 2021 at 2:30pm ET and the Company is participating in the Needham […] » Full Story

CAMBRIDGE, Mass. – January 25, 2021 – Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the Winter Private Company Showcase, co-hosted by Solebury Trout, Oppenheimer and White & Case on Friday, January 29, 2021 at 11am Eastern Time. The presentation will provide an overview of the Company’s […] » Full Story

CAMBRIDGE, MA –November 18, 2020 – Caraway Therapeutics today announced that the Company has been awarded a second research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). This latest grant builds on Caraway’s drug discovery research focused on the role of lysosomal function and autophagy in neurodegenerative and rare diseases to further investigate the […] » Full Story

CAMBRIDGE, MA –November 10, 2020 – Caraway Therapeutics today announced that the Company is scheduled to present at two upcoming virtual conferences during November, 2020. Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 8:40am ET. Caraway’s President and Chief Scientific Officer, Magdalene Moran, […] » Full Story

Caraway Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced it has appointed Martin D. Williams as Chief Executive Officer. » Full Story

Rheostat Therapeutics, an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons, today announced the company has changed its name to Caraway Therapeutics. » Full Story

Rheostat Therapeutics, a biotech company focused on the discovery of novel treatments for neurodegeneration, cognition and rare diseases, today announced the close of a Series A financing round totaling $23 million. » Full Story